ANDON HEALTH(SZ:002432)2026-01-28 10:46Group 1: Product Development and Market Expansion - The iHealth four-in-one test kit received FDA 510(K) pre-market notification in December 2025, allowing it to be sold in the U.S. market, with prices set at $29.99 for two tests and $49.99 for four tests [2][3] - The company is accelerating the development of Continuous Glucose Monitoring (CGM) products in both domestic and international markets, with plans to integrate them into the diabetes care "O+O" model [3][4] - The company is developing an AI-powered smart hearing aid, which utilizes AI neural network algorithms to enhance user experience in various environments [3] Group 2: Diabetes Care "O+O" Model - The "O+O" model focuses on comprehensive diabetes management, combining in-hospital treatment with out-of-hospital support, significantly improving patient outcomes [4][5] - The model has expanded to approximately 50 cities and 424 hospitals in China, managing over 366,000 diabetes patients, with a patient compliance rate improvement from 30% to 60% [5][6] - In the U.S., the company collaborates with about 74 clinics and 394 doctors, serving around 21,000 patients, with significant growth in patient numbers and related revenue [5][6] Group 3: AIoT Diabetes Family Assistant - The AIoT diabetes family assistant aims to enhance the efficiency of care providers by utilizing advanced AI technologies for personalized patient communication and management [7][8] - The project is expected to launch a complete AI module by Q2 2026, with a focus on optimizing healthcare resource allocation and improving primary care services [7][8] - The AIoT initiative has generated valuable private healthcare data, which will be used for training vertical AI models, enhancing the company's capabilities in chronic disease management [8] Group 4: Investment Strategy and Financial Planning - Since 2022, the company has invested over 4.3 billion yuan in various sectors, including hard technology, healthcare, AI, and renewable energy, through partnerships with professional investment institutions [9][10] - The company has initiated a stock buyback plan, having canceled 29,954,222 shares, and aims to distribute at least 30% of cumulative net profits to shareholders over the next three years [10] - The investment strategy is designed to ensure normal business operations and cash flow while navigating the uncertainties associated with long-term returns in the innovation sector [10]